Literature DB >> 27401932

Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine.

Tommy S de Windt1, Juliette C Sorel1, Lucienne A Vonk1, Michelle M A Kip2, Maarten J Ijzerman2, Daniel B F Saris1,3.   

Abstract

Both the complexity of clinically applied tissue engineering techniques for articular cartilage repair - such as autologous chondrocyte implantation (ACI) - plus increasing healthcare costs, and market competition, are forcing a shift in focus from two-stage to single-stage interventions that are more cost-effective. Early health economic models are expected to provide essential insight in the parameters driving the cost-effectiveness of new interventions before they are introduced into clinical practice. The present study estimated the likely incremental cost-effectiveness ratio (ICER) of a new investigator-driven single-stage procedure (IMPACT) compared with both microfracture and ACI, and identified those parameters that affect the cost-effectiveness. A decision tree with clinical health states was constructed. The ICER was calculated by dividing the incremental societal costs by the incremental Quality Adjusted Life Years (QALYs). Costs were determined from a societal perspective. A headroom analysis was performed to determine the maximum price of IMPACT compared with both ACI and microfracture, assuming a societal willingness to pay (WTP) of €30 000/QALY. One-way sensitivity analysis was performed to identify those parameters that drive the cost-effectiveness. The societal costs of IMPACT, ACI and microfracture were found to be €11 797, €29 741 and €6081, respectively. An 8% increase in all utilities after IMPACT changes the ICER of IMPACT vs. microfracture from €147 513/QALY to €28 588/QALY. Compared with ACI, IMPACT is less costly, which is largely attributable to the cell expansion procedure that has been rendered redundant. While microfracture can be considered the most cost-effective treatment option for smaller defects, a single-stage tissue engineering procedure can replace ACI to improve the cost-effectiveness for treating larger defects, especially if clinical non-inferiority can be achieved.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ACI; cost-effectiveness; early health technology assessment; microfracture; single-stage procedure

Mesh:

Year:  2016        PMID: 27401932     DOI: 10.1002/term.2197

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  10 in total

1.  A cost-effective cell- and matrix-based minimally invasive single-stage chondroregenerative technique developed with validated vertical translation methodology.

Authors:  A A Shetty; S J Kim; S Ahmed; S Trattnig; S A Kim; H J Jang
Journal:  Ann R Coll Surg Engl       Date:  2018-03       Impact factor: 1.891

2.  Improved Short-Term Outcomes of Osteochondral Lesions of the Knee Following Arthroscopic Treatment With Bone Marrow Aspirate Concentrate and Cartilage-Derived Matrix.

Authors:  Iciar M Dávila Castrodad; Erica S Simone; Jennifer Kurowicki; Justin X Melendez; Samuel J Mease; Vincent K McInerney; Anthony J Scillia
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-02-24

Review 3.  Microfracture is more cost-effective than autologous chondrocyte implantation: a review of level 1 and level 2 studies with 5 year follow-up.

Authors:  Tommy Frøseth Aae; Per-Henrik Randsborg; Hilde Lurås; Asbjørn Årøen; Øystein Bjerkestrand Lian
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-11-11       Impact factor: 4.342

4.  Augmented cartilage regeneration by implantation of cellular versus acellular implants after bone marrow stimulation: a systematic review and meta-analysis of animal studies.

Authors:  Michiel W Pot; Toin H van Kuppevelt; Veronica K Gonzales; Pieter Buma; Joanna IntHout; Rob B M de Vries; Willeke F Daamen
Journal:  PeerJ       Date:  2017-10-27       Impact factor: 2.984

5.  Health State Utilities in Children and Adolescents With Osteochondritis Dissecans of the Knee.

Authors:  Joshua Adjei; Benedict U Nwachukwu; Yi Zhang; Huong T Do; Daniel W Green; Emily R Dodwell; Peter D Fabricant
Journal:  Orthop J Sports Med       Date:  2019-12-05

6.  Efficacy of one-stage cartilage repair using allogeneic mesenchymal stromal cells and autologous chondron transplantation (IMPACT) compared to nonsurgical treatment for focal articular cartilage lesions of the knee: study protocol for a crossover randomized controlled trial.

Authors:  J V Korpershoek; L A Vonk; E C Kester; L B Creemers; T S de Windt; M M A Kip; D B F Saris; R J H Custers
Journal:  Trials       Date:  2020-10-09       Impact factor: 2.279

7.  Potential of Melt Electrowritten Scaffolds Seeded with Meniscus Cells and Mesenchymal Stromal Cells.

Authors:  Jasmijn V Korpershoek; Mylène de Ruijter; Bastiaan F Terhaard; Michella H Hagmeijer; Daniël B F Saris; Miguel Castilho; Jos Malda; Lucienne A Vonk
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 8.  Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.

Authors:  Maarten J IJzerman; Hendrik Koffijberg; Elisabeth Fenwick; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

9.  Chondral and Osteochondral Femoral Cartilage Lesions Treated with GelrinC: Significant Improvement of Radiological Outcome Over Time and Zonal Variation of the Repair Tissue Based on T2 Mapping at 24 Months.

Authors:  Markus M Schreiner; Marcus Raudner; Pavol Szomolanyi; Kitty Ohel; Livnat Ben-Zur; Vladimir Juras; Vladimir Mlynarik; Reinhard Windhager; Siegfried Trattnig
Journal:  Cartilage       Date:  2020-06-04       Impact factor: 4.634

Review 10.  A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development.

Authors:  Zahra Goudarzi; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Reza Yousefi Zenouz; Akbar Abdollahi Asl; Nader Tavakoli
Journal:  Med J Islam Repub Iran       Date:  2021-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.